$0.17 EPS Expected for AngioDynamics, Inc. (ANGO)

December 8, 2017 - By Marie Mckinney

 $0.17 EPS Expected for AngioDynamics, Inc. (ANGO)
Investors sentiment increased to 2.49 in Q2 2017. Its up 0.91, from 1.58 in 2017Q1. It is positive, as 14 investors sold AngioDynamics, Inc. shares while 27 reduced holdings. 24 funds opened positions while 78 raised stakes. 33.36 million shares or 10.11% more from 30.30 million shares in 2017Q1 were reported.
Tfs Capital Lc has invested 0.35% in AngioDynamics, Inc. (NASDAQ:ANGO). Kentucky-based Teachers Retirement Of The State Of Kentucky has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Parametric Port Assoc Ltd Liability owns 87,325 shares. Amer Intl Gp has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). 16,286 were accumulated by State Teachers Retirement System. Ny State Common Retirement Fund reported 43,720 shares or 0% of all its holdings. Tudor Investment Et Al has invested 0.02% in AngioDynamics, Inc. (NASDAQ:ANGO). Strs Ohio holds 0% or 45,100 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 0% or 786 shares. Gotham Asset Limited Liability Corporation reported 0.02% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Zacks Investment Management has invested 0.01% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). First Quadrant Lp Ca holds 112,463 shares or 0.04% of its portfolio. Systematic Fin Mngmt L P has 376,205 shares. Ahl Llp invested in 54,874 shares or 0.02% of the stock. Arizona State Retirement Sys holds 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO) for 17,796 shares.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.17 EPS on January, 5.They anticipate $0.02 EPS change or 10.53 % from last quarter’s $0.19 EPS. ANGO’s profit would be $6.24M giving it 25.06 P/E if the $0.17 EPS is correct. After having $0.12 EPS previously, AngioDynamics, Inc.’s analysts see 41.67 % EPS growth. The stock increased 0.18% or $0.03 during the last trading session, reaching $17.04. About 208,104 shares traded or 2.46% up from the average. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since December 8, 2016 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 7 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 14% are positive. AngioDynamics had 18 analyst reports since July 24, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, September 23 by Sidoti. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Equal Weight” rating by Barclays Capital on Wednesday, February 8. The stock has “Hold” rating by KeyBanc Capital Markets on Thursday, August 24. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Buy” rating by Canaccord Genuity on Friday, January 8. The firm earned “Sell” rating on Monday, August 31 by Zacks. Barclays Capital maintained it with “Equal-Weight” rating and $16 target in Wednesday, July 19 report. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) has “Hold” rating given on Monday, July 10 by Canaccord Genuity. On Tuesday, April 5 the stock rating was downgraded by Canaccord Genuity to “Hold”. The firm has “Hold” rating given on Tuesday, July 18 by Canaccord Genuity. The stock has “Hold” rating by Canaccord Genuity on Wednesday, May 31.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $625.64 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It has a 172.12 P/E ratio. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: